ArticleOncotarget2018
Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.
Naoto Nishii et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this papercites it